Rong Li

US Patent:

8007790, Aug 30, 2011

Filed:

Oct 2, 2007

Appl. No.:

11/906600

Inventors:

Rong Li - Kansas City MO, US
Xiaogang Li - Prairie Village KS, US

Assignee:

Stowers Institute for Medical Research - Kansas City MO

International Classification:

A61K 39/395
A61K 39/00
A61K 38/00
C07K 16/24

US Classification:

4241301, 4241331, 4241351, 4241411, 4241451, 514 11

Abstract:

The present invention is directed to methods of treating or ameliorating an effect of a polycystic disease. More particularly, the methods include administering to a patient in need thereof an amount of a modulator of a tumor necrosis factor (TNF) pathway, which is sufficient to treat or ameliorate an effect of a polycystic disease. Methods of treating or ameliorating an effect of a polycystic kidney disease (PKD) are also provided. Methods are also provided for identifying a candidate compound that may be effective to treat or ameliorate an effect of a polycystic disease or to increase polycystin-2 (PC2) function or decrease Rab11-Family of Interacting Protein2 (FIP2) function. Further provided are methods for identifying a patient having, or who is at risk for developing, a polycystic disease or who would benefit from treatment with a TNF-alpha inhibitor.

US Patent:

20080207711, Aug 28, 2008

Filed:

Feb 28, 2008

Appl. No.:

12/072740

Inventors:

Rong Li - Kansas City MO, US
Xiaogang Li - Prairie Village KS, US

International Classification:

A61K 31/425

US Classification:

514369

Abstract:

Described herein is a method of treating an ID2-related disorder comprising administering to a patient in need thereof an ID2 inhibitor or derivative thereof.

US Patent:

20120122787, May 17, 2012

Filed:

Jul 9, 2010

Appl. No.:

13/382978

Inventors:

Rong Li - Kansas City MO, US

International Classification:

A61K 31/165
A61K 31/19
A61P 13/12
A61K 31/18
A61K 38/12
A61K 31/357
A61K 31/47
A61K 31/167
A61K 31/426

US Classification:

514 154, 514619, 514616, 514557, 514370, 514465, 514311, 514603, 514604

Abstract:

The present invention is directed to, inter alia, methods of treating or ameliorating an effect of a polycystic disease. This method include administering to a patient in need thereof an amount of a modulator of a histone deacetylase (HDAC) path-way, which is sufficient to treat or ameliorate an effect of a polycystic disease, particularly a polycystic kidney disease.